early-phase
BridgeBio Cuts Gene Therapy Budget by Over $50 Million Following Disappointing Early-Phase Data
BridgeBio, gene therapy, budget cut, early-phase data, CAH treatment, BBP-631, congenital adrenal hyperplasia
Actionable Insights Powered by AI
BridgeBio, gene therapy, budget cut, early-phase data, CAH treatment, BBP-631, congenital adrenal hyperplasia